Bluejay Diagnostics expands federal access via Lovell partnership
TipRanks (Tue, 8-Sep 5:19 PM ET)
Globe Newswire (Tue, 8-Sep 6:30 AM ET)
Globe Newswire (Thu, 13-Aug 6:00 AM ET)
Globe Newswire (Tue, 21-Jul 6:30 AM ET)
Market Chameleon (Thu, 9-Oct 5:52 AM ET)
Market Chameleon (Thu, 9-Oct 3:30 AM ET)
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Bluejay Diagnostics trades on the NASDAQ stock market under the symbol BJDX.
As of September 10, 2026, BJDX stock price was flat at $1.01 with 261,143 million shares trading.
BJDX has a beta of -1.81, meaning it tends to be less sensitive to market movements. BJDX has a correlation of 0.02 to the broad based SPY ETF.
BJDX has a market cap of $1.05 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BJDX traded as high as $9,759.84 and as low as $.82.
BJDX has underperformed the market in the last year with a return of -82.6%, while the SPY ETF gained +17.3%. In the last 3 month period, BJDX fell short of the market, returning -77.5%, while SPY returned +4.7%. However, in the most recent 2 weeks BJDX has outperformed the stock market by returning +11.1%, while SPY returned -1.7%.
BJDX support price is $.93 and resistance is $1.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BJDX shares will trade within this expected range on the day.